All In Biotech

Drug Trial Radar · NCT07816198

A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

354

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • AD-233ADrug

    PO, Once daily(QD), 24 weeks

  • AD-233BDrug

    PO, Once daily(QD), 24 weeks

  • AD-233CDrug

    PO, Once daily(QD), 24 weeks

  • AD-233DDrug

    PO, Once daily(QD), 24 weeks

  • AD-233A PlaceboDrug

    PO, Once daily(QD), 24 weeks

  • AD-233B PlaceboDrug

    PO, Once daily(QD), 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)Time frame: Baseline, Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.